Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis
| Autor: | A.E. van der Bijl, K.H. Han, Ferdinand C. Breedveld, J.K. de Vries-Bouwstra, S. ten Wolde, Yvonne P M Goekoop-Ruiterman, Cornelia F Allaart, M V van Krugten, Ben A. C. Dijkmans |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
musculoskeletal diseases medicine.medical_specialty medicine.drug_class Health Status Immunology Anti-Inflammatory Agents Arthritis Gastroenterology Drug Administration Schedule Arthritis Rheumatoid chemistry.chemical_compound Rheumatology immune system diseases Surveys and Questionnaires Internal medicine medicine Humans Immunology and Allergy Pharmacology (medical) Treatment Failure Functional ability skin and connective tissue diseases Aged business.industry Patient Selection Antibodies Monoclonal Middle Aged medicine.disease Infliximab Discontinuation Surgery Radiography Methotrexate Treatment Outcome chemistry Rheumatoid arthritis Antifolate Corticosteroid business Immunosuppressive Agents Follow-Up Studies medicine.drug |
| Zdroj: | Arthritis & Rheumatism. 56:2129-2134 |
| ISSN: | 1529-0131 0004-3591 |
| Popis: | Objective To evaluate the efficacy of infliximab plus methotrexate (MTX) as induction therapy in patients with early rheumatoid arthritis (RA). Methods Disease-modifying antirheumatic drug (DMARD)–naive patients with active, early RA who were included as group 4 of the BeSt study were initially treated with infliximab (3 mg/kg) in combination with MTX (25 mg/week). The Disease Activity Score (DAS) was measured every 3 months. In patients with persistent low disease activity (DAS ≤2.4) for at least 6 months, the infliximab dosage was tapered and finally discontinued; the MTX dosage then was tapered to 10 mg/week. In patients with a DAS of >2.4, the infliximab dosage was increased (maximum 10 mg/kg), and they were subsequently switched to another DMARD. Except for intraarticular administration, corticosteroids were not permitted. Functional ability and the modified Sharp/van der Heijde score were determined after 2 years of therapy. Results Of the 120 patients, 67 responders (56%) had persistent low disease activity and discontinued infliximab after a median of 9.9 months, with a median MTX dosage of 10 mg/week after 2 years. Ten other patients experienced a disease flare after discontinuation and resumed infliximab after a median of 3.7 months. Thirteen patients did not achieve persistent low disease activity and received infliximab at various dosages. Treatment was unsuccessful in 30 patients. In the 67 responders, the progression of joint damage was lower than in the 30 patients in whom treatment failed. Conclusion Fifty-six percent of patients with active early RA, initially treated with infliximab plus MTX, could discontinue infliximab after achieving a DAS of ≤2.4. Low disease activity was maintained in these patients while the MTX dosage was tapered to 10 mg/week. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text